The Institute of Cancer Research (ICR) has made the case that current regulation can sometimes prevent patient access to innovative medicines, arguing for reform of the system.
The ICR highlights various obstacles to access including issues around combination therapies – a promising area for treatments. While these are becoming more common, and several such treatments are assessed by NICE each year, companies struggle to work together to establish appropriate prices for a combination as a result of competition rules, which may result in them not being available to patients.
Personalised medicine and future-proofing the system are both also flagged as important issues for regulatory systems to resolve. The ICR says:
“Over the past few years, the armamentarium available to us for cancer treatment and care has grown exponentially. Immunotherapy is making great leaps to the clinic, genomics has broadened the potential for personalised medicine, and Big Data and AI are helping us find ways to tackle cancer evolution.
“Regulators are now facing a new challenge, in which they must manage the flow into clinical practice – balancing speed of access to new treatments with their role in ensuring safety and efficacy.”
Read the ICR’s article here.